Acute Effect of a Standardized Botanical Blend Rich in Polyphenols on Cognitive Functions in Healthy Students

Inclusion criteria

• Graduate students (being either at the University or high school), with exam at least every 6 months and attending courses at the equivalent of at least 2 full days each week;
• Male and female subjects (at least 25% of each gender);
• Subjects aged 18 - 25 years (limits included);
• French native speaker;
• Healthy, and especially not suffering from the following diseases, either medically controlled or not:

• depression,
• anxiety disorders,
• diabetes (type I or type II),
• dyslipidemia,
• hypertension,
• any other cardiovascular disease,
• disorder of the thyroid function.
• Not consuming any food supplements (at time of V0 visit) and agreeing not to consume any food supplements until the end of the study;
• No consumption within the last 30 days (30 days before the V0 visit) of drug or food supplement likely to affect the studied parameters,
• Body Mass Index (BMI) < 30 kg/m2;
• Non-smoker;
• No use of narcotics nor cannabis within the last 7 days (the 7 days preceding the V0 visit) and agreeing not to consume such products until the end of the study. The compliance with this criteria will be confirmed by a urine TetraHydroCannabinol (THC) test at the beginning of the testing visits (V1 and V2);
• Subjects capable of and willing to comply with the protocol and to give their written informed consent.

Exclusion criteria

• Exam during the study period;
• Systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg during the V0 visit;
• Currently suffering from or personal history of psychiatric or neurologic disorders (examples: schizophrenia, depression, generalized anxiety disorder, epilepsia) according to the subject's self-declaration;
• Neuroleptic, hypnotic, anxiolytic or antidepressant treatment (whatever the reason) ongoing or stopped since less than 3 months;
• Anti-hypertensive, blood thinner or anticoagulant treatment (eg aspirin > 325mg / day and prescribed as anticoagulant) ongoing or stopped since less than 3 months;
• Venotonic treatment or vasodilator treatment ongoing or stopped since less than 3 months;
• Any other treatment (administered systemically or locally) that may affect the endothelial function (example: statins);
• History of moderate to severe traumatic brain injury and / or intracranial surgery;
• Personal history of Cerebrovascular Accident (CVA);
• Inflammatory bowel disease (examples: Crohn disease, coeliac disease, irritable bowel syndrome) likely to affect the intestinal absorption of the study product components;
• Progressive disease ongoing or resolved since less than one year;
• General anesthesia in the last 7 days or planned in the next 2 weeks;
• Restrictive or unbalanced diet (hypocaloric diet aiming at weight loss, vegan, …) according to the subject's self-declaration at V0;
• Excessive alcohol consumption : more than 2 glasses per day every day;
• Documented food allergy to one of the components of the study product;
• Psychological or linguistic incapability to sign the informed consent;
• Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
• Participation in another biomedical study or during the exclusion period of a previous study;
• Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros.